This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

Search the website

Katie Carter

Senior Associate

Download V Card Document Document
Picture of Katie Carter

About

Katie is a senior associate in the firm’s Corporate and M&A team having joined the firm in 2020. She represents corporate and institutional clients, as well as partnerships and private individuals, across a broad range of transactional real estate services.

She has experience in mergers and acquisitions, joint ventures, private equity, venture capital and corporate restructuring. Katie has acted for companies, entrepreneurs, investors and management teams across a broad range of industry sectors (locally, nationally and internationally).

Katie’s work has had particular focus on life sciences, technology and renewable energy sectors. She also provides advice and support to clients on various corporate and commercial matters including corporate governance, company law and commercial contracts.

She has undertaken a two year secondment at SIMEC Atlantis Energy (SAE), a leading sustainable energy company, during which time she was the primary legal advisor for the SAE group.

Experience

  • Progressive Energy: Advising in connection with a £750 million joint venture with Essar Oil as part of the HyNet project to produce, store and distribute low carbon hydrogen in the NW of England.
  • TegCo GmbH: Advising on the sale of 30% of the shares in the capital of a company responsible for developing an energy from waste facility.
  • SIMEC Atlantis Energy: Advising on the sale of Green Highland Renewables to German energy group, VH Auslandsbeteiligungen.
  • Cumulus Oncology: Advising on a series of investment rounds, and on its collaboration agreement for the development of a cancer tackling molecules.
  • Neurochase: Advising Neurochase, a company established by a world leading scientist who has developed a device for delivery of therapeutics to the central nervous system, with its $25 million collaboration agreement to develop the therapy, with Spark Therapeutics Inc.
  • Calcivis: Advising Calcivis, a company that has developed a biotechnology based dental imaging system detecting early tooth decay, in raising investment finance in 2021, 2022, 2023 and 2024.

Credentials

  • Admitted as a solicitor: England & Wales (2015)